Gossamer Bio Reports $16.9 Million Net Income in Q2 2026, Significant Turnaround from Previous Year

Gossamer Bio, Inc. reported its financial results for the second quarter of 2026, revealing a net income of $16.9 million, a significant turnaround from a net loss of $38.3 million in the same period last year. For the first half of 2026, the company recorded a net loss of $29.8 million, compared to a loss of $74.9 million in the first half of 2025. The improved financial performance was largely attributed to a $43.8 million gain on debt extinguishment, which offset operational losses. Total revenue for the second quarter was $9.2 million, down from $11.5 million year-over-year, while revenue for the first half increased to $26.2 million from $21.4 million, driven by ongoing collaboration with Chiesi Farmaceutici S.p.A.

Operating expenses for the second quarter decreased to $35.3 million from $50.3 million in the prior year, primarily due to a reduction in research and development costs, which fell to $26.4 million from $41.6 million. General and administrative expenses remained relatively stable, increasing slightly to $8.9 million from $8.7 million. The company’s accumulated deficit as of June 30, 2026, stood at $1.47 billion, reflecting the ongoing costs associated with its clinical development programs.

In terms of strategic developments, Gossamer Bio recently completed an exchange offer for its 5.00% Convertible Senior Notes due 2027, resulting in the cancellation of $181 million of these notes. In exchange, the company issued $65.2 million in new 7.50% Convertible Senior Secured First Lien Notes due 2030, along with new shares and warrants. This restructuring is part of the company’s efforts to improve its capital structure and reduce debt obligations. Additionally, Gossamer Bio entered into a Rights Reacquisition Agreement with Chiesi, reacquiring worldwide development and commercial rights to its lead product, seralutinib, which is being developed for pulmonary hypertension.

Operationally, Gossamer Bio has made significant changes to its workforce, reducing its headcount by approximately 46% to streamline operations and cut costs. The company is focusing on advancing seralutinib through clinical trials, with plans to submit a New Drug Application (NDA) to the FDA by September 2026. The company’s cash and cash equivalents, along with marketable securities, totaled $57 million as of June 30, 2026, which management believes will be sufficient to fund operations into the first quarter of 2027. However, the company has expressed concerns about its ability to continue as a going concern if it cannot secure additional funding or achieve commercial success with seralutinib.